All 50 States Join Medicaid Drug Pricing Model, Trump Announces
The president says every state will participate in a Medicaid program aimed at lowering drug prices, but key details remain unclear.
President Trump announced Friday that all 50 states will participate in a Medicaid drug pricing program. Both MedPage Today and STAT report that every state will join, so the two outlets agree on the basic scope of the announcement.
MedPage Today describes the initiative as providing 'most favored nation' pricing to some drugs within Medicaid, bringing their net prices down. STAT reports that Trump promoted pharmaceutical deals offering cheaper drugs to state Medicaid programs, referring to the effort as the GENEROUS program.
The two accounts differ in emphasis. STAT's coverage highlights that many details of the GENEROUS program remain unknown. MedPage Today's report centers on the MFN pricing mechanism. Neither source provides the full list of affected drugs or the expected savings.
Sources · 2
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.